Latest / Breastcancer.org Podcast

Kisqali Plus Femara Seems Best Option for Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer
Dr. Gabriel Hortobagyi is professor of breast medical oncology at the University of Texas MD Anderson Cancer Center. He is a past president of the American Society of Clinical Oncology and is one of the world’s leading authorities on breast cancer treatment. He has published more than 1,000 papers in peer-reviewed journals.
At the European Society for Medical Oncology Congress 2021, Dr. Hortobagyi presented overall survival results from the MONALEESA-2 trial, which compared the combination of Kisqali and Femara to Femara alone to treat advanced-stage hormone-receptor-positive HER2-negative…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.